CalciMedica, Inc.
CALCDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How CALC's past catalysts played out
Auxora
Acute Kidney Injury
Auxora (Part 1)
Pneumonia
CM4620-IE
Acute Pancreatitis
CM-4620 Injectable Emulsion or CM-4620-IE
Acute Pancreatitis
CM4620 Injectable Emulsion (Low Dose)
Acute Pancreatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Auxora | Phase 2 | Acute Kidney Injury | - | - |
Auxora (Part 1) | Phase 2 | Pneumonia | - | - |
CM4620-IE | Phase 2 | Acute Pancreatitis | - | - |
CM-4620 Injectable Emulsion or CM-4620-IE | Phase 2 | Acute Pancreatitis | - | - |
CM4620 Injectable Emulsion (Low Dose) | Phase 2 | Acute Pancreatitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CalciMedica, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in CalciMedica, Inc.'s (CALC) pipeline across Phase 2. Its lead program is Auxora (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CalciMedica, Inc.'s next FDA catalyst?→
CalciMedica, Inc.'s (CALC) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CALC biotech catalysts?→
Add CALC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CalciMedica, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.